Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.

2.

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.

Barbone D, Follo C, Echeverry N, Gerbaudo VH, Klabatsa A, Bueno R, Felley-Bosco E, Broaddus VC.

PLoS One. 2015 Aug 18;10(8):e0134825. doi: 10.1371/journal.pone.0134825. eCollection 2015.

3.

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.

Echeverry N, Ziltener G, Barbone D, Weder W, Stahel RA, Broaddus VC, Felley-Bosco E.

Cell Death Dis. 2015 May 7;6:e1757. doi: 10.1038/cddis.2015.124.

4.

Apoptotic agents.

Fennell DA.

Transl Lung Cancer Res. 2013 Jun;2(3):238-43. doi: 10.3978/j.issn.2218-6751.2013.01.03. Review. No abstract available.

5.

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA.

Cancer Res. 2015 Apr 1;75(7):1399-412. doi: 10.1158/0008-5472.CAN-14-2785. Epub 2015 Feb 24.

6.

Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.

Chimenti MS, Tucci P, Candi E, Perricone R, Melino G, Willis AE.

Cell Cycle. 2013 Sep 15;12(18):3025-36. doi: 10.4161/cc.26067. Epub 2013 Aug 19.

7.

Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.

Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A, Dobra K.

PLoS One. 2013 Jun 20;8(6):e65903. doi: 10.1371/journal.pone.0065903. Print 2013.

8.

A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.

Gurpinar E, Grizzle WE, Shacka JJ, Mader BJ, Li N, Piazza NA, Russo S, Keeton AB, Piazza GA.

Mol Cancer Ther. 2013 May;12(5):663-74. doi: 10.1158/1535-7163.MCT-12-0785. Epub 2013 Feb 26.

9.

AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies.

Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M.

PLoS One. 2013;8(1):e53708. doi: 10.1371/journal.pone.0053708. Epub 2013 Jan 18.

10.

Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC.

PLoS One. 2012;7(12):e52753. doi: 10.1371/journal.pone.0052753. Epub 2012 Dec 26.

11.

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.

Stamelos VA, Redman CW, Richardson A.

J Mol Signal. 2012 Aug 16;7(1):12. doi: 10.1186/1750-2187-7-12.

12.

Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.

Fennell DA, Swanton C.

EPMA J. 2012 Jun 18;3(1):6. doi: 10.1186/1878-5085-3-6.

13.

Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.

Bucur O, Stancu AL, Khosravi-Far R, Almasan A.

Cell Death Dis. 2012 Feb 2;3:e263. doi: 10.1038/cddis.2012.2. No abstract available.

14.

The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures.

Lee JH, Na K, Song SC, Lee J, Kuh HJ.

Oncol Rep. 2012 Apr;27(4):995-1002. doi: 10.3892/or.2012.1650. Epub 2012 Jan 20.

Supplemental Content

Support Center